Tofacitinib: A novel oral Janus kinase inhibitor for rheumatoid arthritis

October 1, 2012

Tofacitinib is a novel JAK inhibitor, selective for JAK 1 and JAK 3.

Related Content:

News | Clinical Pharmacology